On the heels of $250M launch, Centes­sa barges ahead with an IPO to fu­el its 10-in-1 Medicxi pipeline

Francesco De Ru­ber­tis made no se­cret of IPO plans for Centes­sa, his 10-in-1 lega­cy play. Bare­ly two months lat­er, the S-1 is in.

The hot-off-the-press fil­ing de­picts the same grand vi­sion that the long­time VC tout­ed when he did the rounds in Feb­ru­ary: Take the as­set-cen­tric mind­set that he’s been preach­ing at Medicxi over the years, and roll up a bunch of biotech up­starts, with un­re­lat­ed risk pro­files, in­to 1 phar­ma com­pa­ny that can car­ry on the de­vel­op­ment at scale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER